These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus. McCormick LM; Heck PM; Ring LS; Kydd AC; Clarke SJ; Hoole SP; Dutka DP Cardiovasc Diabetol; 2015 Aug; 14():102. PubMed ID: 26253538 [TBL] [Abstract][Full Text] [Related]
28. Glucoregulation has greater impact on cognitive performance than macro-vascular disease in men with type 2 diabetes: data from the Caerphilly study. Gallacher JE; Pickering J; Elwood PC; Bayer AJ; Yarnell JW; Ben-Shlomo Y Eur J Epidemiol; 2005; 20(9):761-8. PubMed ID: 16170659 [TBL] [Abstract][Full Text] [Related]
30. Effects of recent, short-term hyperglycemia on responses to hypoglycemia in humans. Relevance to the pathogenesis of hypoglycemia unawareness and hyperglycemia-induced insulin resistance. Fanelli C; Pampanelli S; Calderone S; Lepore M; Annibale B; Compagnucci P; Brunetti P; Bolli GB Diabetes; 1995 May; 44(5):513-9. PubMed ID: 7729608 [TBL] [Abstract][Full Text] [Related]
31. Glucose intolerance is common in Japanese patients with acute coronary syndrome who were not previously diagnosed with diabetes. Hashimoto K; Ikewaki K; Yagi H; Nagasawa H; Imamoto S; Shibata T; Mochizuki S Diabetes Care; 2005 May; 28(5):1182-6. PubMed ID: 15855586 [TBL] [Abstract][Full Text] [Related]
32. Progression of brain atrophy and cognitive decline in diabetes mellitus: a 3-year follow-up. van Elderen SG; de Roos A; de Craen AJ; Westendorp RG; Blauw GJ; Jukema JW; Bollen EL; Middelkoop HA; van Buchem MA; van der Grond J Neurology; 2010 Sep; 75(11):997-1002. PubMed ID: 20837967 [TBL] [Abstract][Full Text] [Related]
33. Hyperglycemia Reduces Efficiency of Brain Networks in Subjects with Type 2 Diabetes. Kim DJ; Yu JH; Shin MS; Shin YW; Kim MS PLoS One; 2016; 11(6):e0157268. PubMed ID: 27336309 [TBL] [Abstract][Full Text] [Related]
34. General aspects of diabetes mellitus. Alam U; Asghar O; Azmi S; Malik RA Handb Clin Neurol; 2014; 126():211-22. PubMed ID: 25410224 [TBL] [Abstract][Full Text] [Related]
35. Predicting isolated postchallenge hyperglycaemia: a new approach; Tehran Lipid and Glucose Study (TLGS). Hosseinpanah F; Rambod M; Reza Ghaffari HR; Azizi F Diabet Med; 2006 Sep; 23(9):982-9. PubMed ID: 16922704 [TBL] [Abstract][Full Text] [Related]
36. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes; 1995 Nov; 44(11):1249-58. PubMed ID: 7589820 [TBL] [Abstract][Full Text] [Related]
37. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes. Carroll MF; Gutierrez A; Castro M; Tsewang D; Schade DS J Clin Endocrinol Metab; 2003 Nov; 88(11):5248-54. PubMed ID: 14602757 [TBL] [Abstract][Full Text] [Related]
38. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. Diabetes Care; 1999 Jul; 22(7):1125-36. PubMed ID: 10388978 [TBL] [Abstract][Full Text] [Related]
39. Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes. Rathmann W; Strassburger K; Bongaerts B; Bobrov P; Kuss O; Müssig K; Markgraf DF; Szendroedi J; Herder C; Roden M; Diabetes Obes Metab; 2017 Jun; 19(6):866-873. PubMed ID: 28127851 [TBL] [Abstract][Full Text] [Related]